Improving Treatment of Inflammatory Bowel Diseases Through Better Understanding Infliximab Drug and Antibody Levels
NCT01787786 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2015-12-03
Summary
The purpose of this study is to develop a predictive model that will allow optimized dosing of infliximab for individual patients
Conditions
Sponsors & Collaborators
-
University of Western Ontario, Canada
lead OTHER
Principal Investigators
-
Brian Feagan, MD · Robarts Clinical Trials - Western University
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Primary Completion
- 2017-03-31
- Completion
- 2017-09-30
More Related Trials
-
Model-informed Dose De-escalation of Infliximab in Patients With Inflammatory Bowel Diseases
NCT04982172 ·Status: COMPLETED ·Phase: PHASE4
-
Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission
NCT01817426 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies in Chronic Inflammatory Diseases
NCT03370601 ·Status: TERMINATED ·Phase: NA
-
Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis
NCT03765450 ·Status: ACTIVE_NOT_RECRUITING
-
Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab
NCT02453776 ·Status: COMPLETED ·Phase: PHASE4
-
Individualized Infiximab Dosing-Proof of Concept Study
NCT02027727 ·Status: UNKNOWN
-
A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Moderate to Severe Active Crohn's Disease
NCT00207662 ·Status: COMPLETED ·Phase: PHASE3
-
Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease
NCT01442025 ·Status: COMPLETED ·Phase: PHASE4
-
Infliximab, Regulatory T Cells, IL2 and Crohn's Disease
NCT01266785 ·Status: WITHDRAWN ·Phase: NA
-
A Study of the Safety and Efficacy of Infliximab (Remicade) in Pediatric Patients With Crohn's Disease
NCT00207675 ·Status: COMPLETED ·Phase: PHASE3
-
Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease
NCT04974099 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Treatment With Infliximab in a Medical Setting (Study P05587)
NCT00752622 ·Status: TERMINATED ·Phase: PHASE4
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
NCT05230173 ·Status: RECRUITING ·Phase: NA
-
Precision IFX: Using a Dashboard to Individualize Infliximab Dosage
NCT02624037 ·Status: COMPLETED ·Phase: NA
-
Research and Follow-up of the Determinants of the Progression and Complications of Inflammatory Bowel Diseases Treated or Not With Immunosuppressants.
NCT07172945 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Construction and Validation of a Predictive Model for the Efficacy of Different Biologics in Inflammatory Bowel Disease
NCT07181525 ·Status: RECRUITING
-
PET/CT to Predict Response to Infliximab Therapy in Patients With Crohn's Disease
NCT01759017 ·Status: TERMINATED
-
Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy
NCT00851565 ·Status: UNKNOWN ·Phase: PHASE4
-
Study to Determine Relationship Between Serum Infliximab and Efficacy in Luminal Crohn's Disease Patients
NCT00676988 ·Status: COMPLETED
-
De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease
NCT04646187 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
TITRATE (inducTIon for acuTe ulceRATivE Colitis)
NCT03937609 ·Status: TERMINATED ·Phase: PHASE4
-
The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy
NCT01181765 ·Status: COMPLETED ·Phase: PHASE4
-
"Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial"
NCT02452151 ·Status: UNKNOWN ·Phase: PHASE4
-
The Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's Disease
NCT02453607 ·Status: UNKNOWN
-
Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis
NCT02438410 ·Status: COMPLETED